



## ATLAVAC H9N2

Inactivated vaccine in oily adjuvant against avian influenza type h9n2.

### THERAPEUTIC CLASS:

Inactivated avian virus vaccine in injectable emulsion.

### PHARMACEUTICAL FORM :

Water-in-oil emulsion for injection

### QUALITATIVE AND QUANTITATIVE COMPOSITION:

For a vaccine dose of 0.25 ml:

#### Active ingredient :

Inactivated avian influenza virus type H9N2, strain Maroc1/16: At least 107 DIO50 before inactivation\*

\* Minimum dose inducing a serological titer inhibiting haemagglutination  $\geq 5 \log_2$ .

**Excipients and adjuvant:** Sufficient quantity for one vaccine dose

### PRESENTATION :

Polypropylene bottles of 500 ml (2000 doses).

### NATURE AND COMPOSITION OF CONTAINERS:

500ml capacity polypropylene bottles.

Elastomer stoppers based on nitrile derivatives.

Aluminum caps.

### SPECIES CONCERNED:

Hen species (broiler, future laying and breeding pullets).

### PHARMACEUTICAL PROPERTIES:

Avian Influenza under the H9N2 type is an infectious disease, very contagious, due to an *Orthomyxovirus* type *Influenza A*, hemagglutinating, weakly pathogenic but can cause significant morbidity and mortality in poultry, especially in chicken **farms**. The only way Effective control and control of this disease is the vaccination of birds with inactivated virus vaccines produced from strains whose **phylogeny and antigenic properties** are homologous to **the local wild strain responsible for the epidemic**.

ATLAVAC H9N2 is an inactivated vaccine in the form of an injectable emulsion against the H9N2 subtype of the Avian Influenza virus. This vaccine is produced from a local **Moroccan strain**, isolated locally and cultured on embryonated chicken eggs SPF of 10 + 1 day.

The viral suspension obtained is inactivated and then adjuvanted with mineral oil.



The minimum content of each vaccine dose is 107 DIO50 before inactivation capable of inducing seroconversion in vaccinated birds at a titer  $\geq 5 \log_2$  allowing active immunization of vaccinated subjects against the H9N2 subtype of Avian Influenza.

**THERAPEUTIC INDICATIONS:** Active

immunization of the hen species against the H9N2 subtype of avian influenza.

**CONTRAINDICATIONS:**

Sick animals should be excluded from vaccination.

The use of the vaccine is not recommended within 2 weeks before the start of lay and during the laying period.

**USUAL DOSAGE:**

**Broiler :** Administer a dose of **0.25ml** per bird, during the first week of age.

**Future laying and breeding** pullets : Administer a dose of **0.25ml** during the first week of age and a possible booster of 0.3ml **per dose, 4 weeks** before the onset of lay.

**METHOD AND ROUTE OF ADMINISTRATION :**

The vaccine is administered intramuscularly in the breast bone or subcutaneously in the lower part of the neck.

Subcutaneous injection is performed by pinching the skin between the thumb and index finger at the level of the lower part of the neck, then introducing the needle under the skin in the opposite direction to the chick's head and injecting the recommended dose.

**WARNINGS:**

Avoid exposing birds to stress during and after vaccination.

Do not place birds in a contaminated environment.

Minimize the risk of exposure to disease.

For veterinary use only.

**SPECIAL PRECAUTIONS FOR USE:**

**Special precautions for use in animals:**

- ÿ Only vaccinate healthy birds.
- ÿ Bring the vial to room temperature for approximately two hours before proceeding with injection.
- ÿ Before use, homogenize the emulsion by shaking the bottle and from time to time during injection.
- ÿ Use sterile equipment for injection
- ÿ Avoid the use of syringes whose plunger is made of natural rubber or derivatives of butyl.
- ÿ As the vaccine dose is small, regularly check the volume injected during the vaccination.
- ÿ Use the entire contents of the bottle after opening.



**Special precautions to be taken by the person administering the veterinary medicinal product to animals:**

• This vaccine contains mineral oil, its accidental injection in humans can lead to significant pain and edema which can induce necrotizing ischemia. • In case of accidental injection at the manipulator, immediately notify a doctor even if the injected dose is very low.

**Other precautions:**

None.

**USE DURING THE LAYING PERIOD:**

Do not use within 2 weeks before the onset of lay and during lay.

**OVERDOSAGE (SYMPTOMS, EMERGENCY MANAGEMENT, ANTIDOTES) IF NECESSARY:**

No adverse effects were observed after administration of twice the vaccine dose.

**INCOMPATIBILITIES**

Do not mix with other drugs.

**POSSIBLE DRUG INTERACTIONS:** No information is available on the safety

and efficacy of combining this vaccine with any other veterinary medicinal product. Therefore, the decision to use this vaccine before or after any other veterinary medicinal product should be made on a case-by-case basis.

**SIDE EFFECTS :**

The vaccine used according to the recommended instructions does not induce any side effects.

**VALIDITY PERIOD:**

Unopened bottle: 24 months

After opening: immediate use

**SPECIAL STORAGE CONDITIONS:**

Store and transport the vaccine at a temperature between +2°C and +8°C, protected from light. Do not freeze

**WITHDRAWAL PERIOD**

Zero days.